drugset / Trial / NCT01681472

PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer

NCT01681472

Phase 1/2 Completed 32 enrolled Isofol Medical AB
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare the concentration of four different metabolites in the tumor, in adjacent mucosa and in plasma in patients with colon cancer receiving two different doses of Modufolin (arfolitixorin) and Levoleucovorin (Isovorin®), respectively (60 and 200 mg/m2).

Timeline

Start
2012-09
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Arfolitixorin Small molecule 60 mg/m2 Intravenous
Subject Arfolitixorin Small molecule 200 mg/m2 Intravenous
Comparator Levoleucovorin Unknown 60 mg/m2 Intravenous
Comparator Levoleucovorin Unknown 200 mg/m2 Intravenous

Indications